Strain Information | |
---|---|
Image | |
BRC No. | RBRC10042 |
Type | Targeted Mutation |
Species | Mus musculus |
Strain name | B6.Cg-Mapt<tm1.1(MAPT)Tcs> App<tm2(NL-F)Tcs> |
Former Common name | |
H-2 Haplotype | |
ES Cell line | |
Background strain | |
Appearance | |
Strain development | |
Strain description | |
Colony maintenance | |
References | Recent Advances in the Modeling of Alzheimer's Disease. Hiroki Sasaguri, Shoko Hashimoto, Naoto Watamura, Kaori Sato, Risa Takamura, Kenichi Nagata, Satoshi Tsubuki, Toshio Ohshima, Atsushi Yoshiki, Kenya Sato, Wakako Kumita, Erika Sasaki, Shinobu Kitazume, Per Nilsson, Bengt Winblad, Takashi Saito, Nobuhisa Iwata, Takaomi C Saido Front. Neurosci., 16:807473 (2022). 35431779Single App knock-in mouse models of Alzheimer's disease. Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido T C Nat. Neurosci., 17(5):661-663 (2014). 24728269Tau binding protein CAPON induces tau aggregation and neurodegeneration. Hashimoto S, Matsuba Y, Kamano N, Mihira N, Sahara N, Takano J, Muramatsu S I, Saido T C, Saito T Nat. Commun., 10(1):2394 (2019). 31160584Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation. Saito T, Mihira N, Matsuba Y, Sasaguri H, Hashimoto S, Narasimhan S, Zhang B, Murayama S, Higuchi M, Lee V M Y, Trojanowski J Q, Saido T C J. Biol. Chem., 294(34):12754-12765 (2019). 31273083 |
Health Report | |
---|---|
Examination Date / Room / Rack |
Gene | |||||||
---|---|---|---|---|---|---|---|
Gene Symbol | Gene Name | Chr. | Allele Symbol | Allele Name | Common Names | Promoter | Diseases Related to This Gene |
Frt | yeast FRT (flippase recombination target) site | 11 | Frt | ||||
MAPT | microtubule-associated protein tau (human) | 11 | MAPT | ||||
Mapt | microtubule-associated protein tau | 11 | Mapt | targeted mutation 1.1, Takaomi C. Saido | |||
loxP | phage P1 loxP | 11 | loxP | ||||
App | amyloid beta precursor protein | 16 | App | targeted mutation 2, Takaomi C. Saido | |||
Frt | yeast FRT (flippase recombination target) site | 16 | Frt | ||||
loxP | phage P1 loxP | 16 | loxP |
Phenotype | |
---|---|
Annotation by Mammalian phenotyhpe ontology | |
Detailed phenotype data |
Ordering Information | |
---|---|
Donor DNA | human MAPT genomic DNA, yeast FRT site, Phage P1 loxP site, mouse Mapt genomic DNA, phage P1 loxP site, yeast FRT (flipase recombination target) site, mouse App genomic DNA (mutant type) |
Research application | Cre/loxP system FLP/frt system Mouse Models for Human Disease |
Specific Term and Conditions | The BIOLOGICAL RESOURCE is the property of the RIKEN (The Institute of Physical and Chemical Research). RECIPIENT agrees to acknowledge Shoko HASHIMOTO, Takashi SAITO and Takaomi C. SAIDO in an acknowledgement section. RECIPIENT also agrees to cite Nature Neuroscience 17, 661-663 (2014), Nature Communications 10: 2394 (2019) and Journal of Biological Chemistry, 294: 12754-12765 (2019) in all publications obtained using BIOLOGICAL RESOURCE. RECIPIENT agrees to acknowledge DEPOSITOR in all oral presentations and written publications as related to the BIOLOGICAL RESOURCE. RECIPIENT shall keep confidential any or all information marked CONFIDENTIAL that is received from DEPOSITOR and related to the BIOLOGICAL RESOURCE including oral discussions if they are reduced to writing within thirty (30) days and are marked "CONFIDENTIAL". For-profit organizations must contact the DEPOSITOR (takaomi.saido@riken.jp) for a licensing contract. If any invention is conceived and reduced to practice by RECIPIENT in the performance of the Research Plan involving the BIOLOGICAL RESOURCE during the term of this MTA, RECIPIENT agrees to promptly inform the invention to DEPOSITOR and the parties will consult each other to determine inventorship and ownership of the invention based on the respective parties contribution to the invention, before filing an application for a patent. In the case of a jointly owned application, the parties will separately enter into a joint application agreement including the sharing of ownership, patent costs and licensing income, as well as the responsible party for the application procedures etc. |
Depositor | Takaomi C. Saido (RIKEN CBS) |
Strain Status | Frozen embryos Frozen sperm |
Strain Availability | Recovered litters from cryopreserved embryos (2 to 4 months) Cryopreserved sperm (within 1 month) Cryopreserved embryos (within 1 month) |
Additional Info. | Necessary documents for ordering:
Genotyping protocol -PCR- |
BRC mice in Publications |
---|
Hiroki Sasaguri, Shoko Hashimoto, Naoto Watamura, Kaori Sato, Risa Takamura, Kenichi Nagata, Satoshi Tsubuki, Toshio Ohshima, Atsushi Yoshiki, Kenya Sato, Wakako Kumita, Erika Sasaki, Shinobu Kitazume, Per Nilsson, Bengt Winblad, Takashi Saito, Nobuhisa Iwata, Takaomi C. Saido Recent Advances in the Modeling of Alzheimer’s Disease Frontiers Neuroscience 16 (2022) 35431779 |